From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)
Cancers. 2017;9(12):138 
Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers
Cancers. 2017;9(12):148
Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
Journal of Korean Medical Science. 2018;33(15):
Anaplastic lymphoma kinase (ALK) inhibitors in the treatment of ALK-driven lung cancers
Pharmacological Research. 2017;117:343-356
Mouse models of anaplastic lymphoma kinase (ALK)-induced B cell leukemia and lymphoma
Science-Business eXchange. 2010;3(18):571-571
Crizotinib
Reactions Weekly. 2017;1668(1):131-131
Recurrence of anaplastic lymphoma kinase (ALK) positive adenocarcinoma after 17 years: Case report
Cancer Treatment Communications. 2015;4:6-9
Copy number gain in recurrent anaplastic lymphoma kinase (ALK
) rearrangement-lung adenocarcinoma in the pleural effusion
Diagnostic Cytopathology. 2018;
Alectinib
Reactions Weekly. 2018;1695(1):24-24
An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive
Cancers. 2017;9(12):141